Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 2/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 2/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | BRS3 | P32247 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12775584 | 0.83 | TSHR (0.35) | TSHRSCN10ASCN5AMAPTHTR1B | |
| SCHEMBL14012154 | 0.82 | TSHR (0.38) | TSHRGSK3BSCN10ASCN5AKDM4E | |
| Hydrochloric Acid SCHEMBL8115736 | 0.80 | TSHR (0.37) | TSHRGSK3BSCN10ASCN5AKDM4E | |
| SCHEMBL21350694 | 0.79 | BRS3 (0.44) | TSHRGSK3BKDM4EMAPTBRS3 | |
| SCHEMBL14037799 | 0.78 | — | — | |
| SCHEMBL7484552 | 0.78 | GLA (0.39) | TSHRKDM1AHTR1BMTORHRH1 | |
| SCHEMBL14012158 | 0.75 | DGAT1 (0.38) | TSHRHTR1BMTORHRH1HRH4 | |
| SCHEMBL1691973 | 0.75 | BRS3 (0.43) | BRS3 | |
| SCHEMBL22871224 | 0.74 | TSHR (0.42) | TSHRGSK3BSCN10ASCN5AKDM4E | |
| SCHEMBL7484547 | 0.72 | CAPN1 (0.33) | KDM1AHRH1HRH4BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011613-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2018-07-03 | — | — | US | disclosed |
| US-20170226128-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011613-B2 | Polycyclic pyridone derivative having integrase inhibitory activity | TYMP, CDK6, IMPA1 | TSHR 4574/4885GSK3B 660/4885SCN10A 4740/4885 |
| US-20170226128-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | TYMP, CDK6, IMPA1 | TSHR 4574/4885GSK3B 660/4885SCN10A 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.